New commitment from LSIF

The focus of LSIF is commercial stage companies, but if other cases are compelling enough, we can make exceptions. One such exception in the past were Fluoguide - our first investment.
Now we have chosen to support Lipidor (ticker LIPI on Nasdaq First North Growth Market) as one of the leading guarantors in the upcomming rights issue.
Lipidor has in october 2022 missed the primary goal in a phase III trial with APK02 for treatment of psoriasis. Since then the reason has been identified and corrected in a new formulation, which is now in a renewed phase III study. We estimate that the probability of Lipidor's success in the new study is significantly higher than normal, and that Lipidor is therefore an exciting investment case for us at a very low valuation. One should be aware though, that it is a binary outcome.